Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers

Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and ...
Stocktwits on MSN

Disc Medicine, Sanofi, Eli Lilly shares slip on reports of FDA increasing review time for drugs granted priority review vouchers

FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10 ...

Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance

Disc Medicine (IRON) has drawn fresh attention after securing priority FDA review for bitopertin and outlining ...
TMCnet

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...